Last Updated: September 28, 2026

Details for New Drug Application (NDA): 202799


✉ Email this page to a colleague

« Back to Dashboard


NDA 202799 describes OMONTYS PRESERVATIVE FREE, which is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug. Additional details are available on the OMONTYS PRESERVATIVE FREE profile page.

The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. There is one drug master file entry for this compound. Additional details are available on the peginesatide acetate profile page.
Summary for 202799
Tradename:OMONTYS PRESERVATIVE FREE
Applicant:Takeda Pharms Usa
Ingredient:peginesatide acetate
Patents:2

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUS, SUBCUTANEOUSStrengthEQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)
Approval Date:Mar 27, 2012TE:RLD:No
Patent:7,550,433Patent Expiration:Jun 2, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Patent:7,919,461Patent Expiration:Jun 2, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUS, SUBCUTANEOUSStrengthEQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)
Approval Date:Mar 27, 2012TE:RLD:No
Patent:7,550,433Patent Expiration:Jun 2, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Expired US Patents for NDA 202799

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 7,414,105 ⤷  Start Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 7,528,104 ⤷  Start Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-002 Mar 27, 2012 7,550,433 ⤷  Start Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 7,919,118 ⤷  Start Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 7,919,461 ⤷  Start Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 7,550,433 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or Start Trial

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links